.jpg)
2 hours ago
4
Article content
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
LONDON — Citi Issuer Services, acting through Citibank N.A., has been appointed by Vicore Pharma Holding AB (“Vicore Pharma”), a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), to act as Depositary Bank for its sponsored Level 2 American Depositary Receipt (“ADR”) program.
Article content
Article content
Vicore Pharma’s ADRs trade on the Nasdaq Capital Market under the symbol “VCRE”. Each ADS represents ten ordinary shares of the company. Vicore Pharma’s underlying ordinary shares are listed and traded on the Nasdaq Stockholm Stock Exchange under the symbol “VICO”.
Article content
Article content
Commenting on the appointment, Dirk Jones, Head of Issuer Services at Citi, said: “We are committed to supporting Vicore Pharma with high quality services through our industry-leading ADR solutions. Our deep capital markets expertise and extensive global network enable us to facilitate seamless access to global capital markets for issuers like Vicore Pharma.”
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
Citi Issuer Services is a leading provider of depositary receipt services. With depositary receipt programs in over 65 markets, spanning equity and fixed-income products, Issuer Services leverages Citi’s global network to provide cross-border capital market access to issuers, intermediaries, and investors.
Article content
About Citi
Article content
Citi is a preeminent banking partner for institutions with cross-border needs, a global leader in wealth management and a valued personal bank in its home market of the United States. Citi does business in more than 180 countries and jurisdictions, providing corporations, governments, investors, institutions and individuals with a broad range of financial products and services.
Article content
Article content
Article content
Article content
View source version on businesswire.com:
Article content
Article content
Article content
Contacts
Article content
Citi Media Contact:
Article content
Article content
Harsha Jethnani
Article content
Article content
Article content
Article content
+65 93830872
Article content
English (US)